Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (33,277)	$ (69,442)
Adjustments to reconcile net loss used in operating activities:
Stock-based compensation	5,622	7,683
Acquired in-process research & development	0	47,716
Depreciation and amortization	785	340
Loss on disposal of property and equipment	180	5
Amortization of right-of-use asset	1,036	188
Write-off of right-of-use asset upon lease termination	113	0
Unrealized foreign exchange loss and others	0	70
Changes in operating assets and liabilities:
Other current assets and non-current assets	(2,481)	290
Accounts payable and accrued liabilities	3,018	(2,007)
Operating lease right-of-use assets	(169)	0
Operating lease liabilities	598	(237)
Net cash used in operating activities	(24,575)	(15,394)
Investing activities
Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired	0	191
Purchase of property and equipment	(2,219)	(879)
Net cash used in investing activities	(2,219)	(688)
Financing activities
Proceeds from public offering of common stock and pre-funded warrants, net of commissions of $4,575 and $5,173 in 2020 and 2019, respectively.	71,675	81,043
Payment of offering costs	(355)	(352)
Proceeds from exercise of stock options	5,665	1,555
Proceeds from issuance of common stock under Employee Stock Purchase Plan	199	0
Payment on finance lease obligations	(49)	(9)
Net cash provided by financing activities	77,135	82,237
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	0	10
Net change in cash, cash equivalents, and restricted cash during the year	50,341	66,165
Cash, cash equivalents, and restricted cash at beginning of year	143,093	76,928
Cash, cash equivalents, and restricted cash at end of year	193,434	143,093
Non-cash investing and financing activities:
Other current assets acquired through the issuance of common stock	0	560
Property, equipment and intangibles acquired through the issuance of common stock	0	1,693
Accounts payable, finance lease and other liabilities assumed through the issuance of common stock	0	(1,673)
Operating lease liabilities arising from obtaining right-of-use asset	10,364	1,182
Purchase of property and equipment unpaid at period end	$ 36	$ 0